Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000457 · ClinicalTrials.gov registry record · Phase 2
Pharmacologic Relapse Prevention for Alcoholic Smokers
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
NCT00000457: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00000457 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 195 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000457, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
Study Summary
This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
Interventions
- DRUG Placebo
- DRUG bupropion (Wellbutrin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 1998-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000457
The ClinicalTrials.gov registry entry for NCT00000457 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00000457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000457 about?
NCT00000457 is a clinical study titled "Pharmacologic Relapse Prevention for Alcoholic Smokers". This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment am...
What is the current status of trial NCT00000457?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 1998-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00000457?
The interventions under investigation include: Placebo (DRUG), bupropion (Wellbutrin) (DRUG).
Who is sponsoring clinical trial NCT00000457?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.